BRANY Announces 5-Year Accreditation
BRANY has successfully continued its Full Accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). The five-year accreditation reflects BRANY’s continuing commitment to protecting the rights and welfare of research participants. AAHRPP’s accreditation process help organizations consistently meet ethical principles and standards for protecting research participants.
“We are pleased to have earned this ‘gold seal’ for the 3rd consecutive time,” says Raffaella Hart, CIP, Vice President of BRANY IRB and IBC Services. “For over 15 years, BRANY has strived to meet and exceed regulatory compliance standards while focusing on strengthening protections for study participants.”
To prepare for the reaccreditation process, BRANY completed a detailed self-assessment that included a thorough review of the policies and procedures of its Human Research Protection program, which includes BRANY’s Institutional Review Board (BRANY IRB). The effort is designed to ensure regulatory compliance as well as compliance with AAHRPP’s standards, and is followed by an extensive site visit by AAHRPP representatives to evaluate the records and confirm processes are aligned with policies and procedures.
Once an organization achieves accreditation, subsequent programmatic changes must account for both regulatory standards and how the accreditation standards will be maintained. Accreditation requires an ongoing commitment to protection of human subjects and maintenance of best practices.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025